Navigation Links
GenturaDx to Host Poster Presentation at Association for Molecular Pathology 2011 Annual Meeting
Date:11/14/2011

HAYWARD, Calif., Nov. 14, 2011 /PRNewswire/ -- GenturaDx today announced that it will present data from alpha studies performed in Q2 2011 at the Association for Molecular Pathology 2011 Annual Meeting on Friday, November 18 from 2:15 p.m. to 3:30 p.m. Poster number ID 23 titled "Comparison Of Assay Performance Between Cell Culture And A Rapid Automated Molecular Test For HSV Typing Of Clinical Samples" will address the capability of the GenturaDx IDbox™ System to detect HSV 1/2 as compared with non-molecular methods. Lead author Nathalie Visomblin, Chief Scientific Officer/Co-Founder Dr. Jesus Ching, and Senior Vice President of Research and Development Dr. Geoff McKinley will be on hand to answer questions.

The GenturaDx IDbox™ System will be on display at booth 721. GenturaDx's fully automated molecular diagnostics platform, the IDbox™ System and its initial HSV 1/2 assay, are currently in beta testing with clinical trials beginning in 2012. The IDbox™ System is a compact, fully integrated system that can handle multiple sample types and assay chemistry options. With a broad menu of infectious disease tests and a true press play and walk away technology, the IDbox™ System will be the first to enable labs to meet both increasing clinical demand for molecular testing while maximizing laboratory efficiency.

About GenturaDx

GenturaDx is a molecular diagnostic company focused on making high-performance molecular diagnostics both affordable and practical for any laboratory to perform.  The company is developing a fully integrated, automated instrument that conducts testing using a single-use cassette. This platform will make rapid, high-quality molecular diagnostics accessible to hospitals and patients worldwide – circumventing long-standing barriers of costs, automation and performance. GenturaDx's compact, self-contained platform incorporates sample preparation with proprietary, real-time
'/>"/>

SOURCE GenturaDx
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. GenturaDx Appoints Senior Vice President of Research & Development
2. Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
3. Monogram Announces Posters to be Presented at the 30th San Antonio Breast Cancer Symposium
4. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
5. Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO)
6. CNS Response, Inc. Provides Review of Poster Session Delivered at the American Psychiatric Association 161st Annual Meeting
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Novexel to Present Five Posters at the Joint Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Disease Society of America (ICAAC/IDSA) Meeting
9. Novexel to Present Four Posters at the 19th European Congress of Clinical Microbiology and Infectious Diseases in Helsinki
10. PharmaNet Development Group To Showcase Innovative Solutions and Poster Presentations at AAPS 2009
11. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: Global Markets ... -- Focus on End Users ... A drug delivery system is ...
(Date:1/15/2014)... CAMBRIDGE, Mass. , Jan. 15, 2014  Zafgen, ... the unmet needs of severely obese patients, today ... of beloranib, a selective inhibitor of methionine aminopeptidase ... a severe form of genetic obesity.  These results ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... 2009 Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ) today reported ... Arena reported a lower net loss allocable to common stockholders in ... share, compared to a net loss allocable to common stockholders in ... share, and a net loss allocable to common stockholders in the ...
... TessArae® LLC, a global leader in resequencing microarray-based ... solutions for genetic testing of the mutations that ... TessArae,s expertise in microarray-based resequencing with novel nucleotide ... for all targeted mutations in multiple genes of ...
Cached Medicine Technology:Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 2Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 3Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 4Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 5Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 6Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 7Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 8Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 9TessArae Delivers Lower Cost Option to Genetic Testing Market 2
(Date:4/24/2014)... three survivors of critical illness, according to a ... Medicine , and the majority of patients experience ... is one of the largest studies to investigate ... care survivors, according to lead author James Jackson, ... a significant public health issue, with roughly 5 ...
(Date:4/24/2014)... first in the world to discover a gene mutation ... , Ameloblastoma is an odontogenic tumour with a high ... found in the posterior of the lower jaw. Ameoloblastomas ... in the jaws as well as loss of several ... for surgery and the recurrence of ameloblastoma, but finding ...
(Date:4/24/2014)... State University researcher has found a relationship between motor ... autism spectrum disorder in very young children. , ... show a direct relationship between motor skills and autism ... skills should be included in treatment plans for young ... in OSU,s College of Public Health and Human Sciences. ...
(Date:4/24/2014)... 2009 the influenza pH1N1 virus caused the first flu ... in May 2009 and killed more than 50 people ... Finns mainly during flu epidemics (winter/spring seasons). , ... serious complicated illnesses. World Health Organization has recommended Tamiflu ... The disadvantage of this drug is that it targets ...
(Date:4/23/2014)... A pilot study by Massachusetts General Hospital (MGH) investigators ... unusual treatment for a serious medical problem use ... diarrhea caused by the Clostridium difficile ( ... published online in the journal Clinical Infectious Diseases ... fecal material from donors unrelated to patients was as ...
Breaking Medicine News(10 mins):Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 3Health News:Motor skill deficiencies linked to autism severity in new research 2Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 2Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 3
... a global,provider of products and services that improve the ... for the medical technology company that will,be formed through ... , The new company will ... the company will offer to improve the safety and ...
... The DRE VSE Series includes a variety of affordable, dependable surgery ... ... (Vocus) February 16, 2009 -- DRE Veterinary — a ... VSE Series, a line of surgical and exam tables. All DRE ...
... (February 15, 2009)P&G Beauty & Grooming scientists are presenting ... that offers evidence of science,s role in evolving beauty ... observes the 200th anniversary of Charles Darwin,s birth, affording ... advanced science and technology to help individuals feel and ...
... re-newed demand for affordable drug rehabs - Mountainside Drug Rehab Center ... an inpatient substance abuse treatment curriculum that has been replicated by ... ... (PRWEB) February 15, 2009 -- The economy has been under extraordinary ...
... ROCK HILL, S.C., Feb. 14 A York County jury ... child who suffered a brain injury at birth. The award ... at fault when it assigned a nurse trainee to monitor ... with nausea and vomiting. The nurse misread fetal heart monitoring ...
... males face higher risk of fathering children with medical problems, ... wasn,t all that long ago that any suggestion that a ... father children sooner rather than later, would have been given ... of evidence suggests that as men get older, fertility can ...
Cached Medicine News:Health News:Cardinal Health Announces New Name for Spinoff Company 2Health News:Cardinal Health Announces New Name for Spinoff Company 3Health News:Cardinal Health Announces New Name for Spinoff Company 4Health News:DRE Veterinary Unveils Line of Surgical and Exam Tables 2Health News:DRE Veterinary Unveils Line of Surgical and Exam Tables 3Health News:DRE Veterinary Unveils Line of Surgical and Exam Tables 4Health News:Beauty and grooming science evolves 2Health News:Beauty and grooming science evolves 3Health News:Drug Rehab Mountainside Treatment Center is an Effective and Quality Option for Those Seeking Drug Treatment - Located Close to NY MA 2Health News:Men Must Contend With a Biological Clock, Too 2Health News:Men Must Contend With a Biological Clock, Too 3
These simple but effective single-dose, hands-off, ampulized applicators have revolutionized skin preparation in hospitals....
... Anti-HTLV Mixed Titer Performance Panel consists of ... to strong positive for antibodies to HTLV ... for use by manufacturers and diagnostic laboratories ... data from all major test systems are ...
Comprised of a monofilament polypropylene mesh coated with hydrophilic porcine collagen, Pelvitex™ mesh is clinically proven coating to enhance the healing process, along with the strength and d...
The Repliform Tissue Regeneration Matrix is an acellular human dermal allograft that when surgically implanted is intended to function as a template, facilitating the body's fibroblasts to regenerate...
Medicine Products: